5

Abstract

The invention is directed to methods to inhibit TGF- β and/or p38- α kinase using compounds of the formula

$$Z_{1}^{6}$$

$$Z_{2}^{7}$$

$$Z_{1}^{8}$$

$$Z_{1}^{8}$$

$$Z_{1}^{8}$$

$$Z_{1}^{3}$$

$$Z_{1}^{3}$$

$$Z_{1}^{3}$$

$$Z_{2}^{3}$$

$$Z_{1}^{3}$$

$$Z_{1}^{3}$$

$$Z_{2}^{3}$$

$$Z_{1}^{3}$$

$$Z_{2}^{3}$$

$$Z_{1}^{3}$$

$$Z_{2}^{3}$$

$$Z_{1}^{3}$$

$$Z_{2}^{3}$$

$$Z_{3}$$

$$Z_{1}^{3}$$

$$Z_{2}^{3}$$

$$Z_{1}^{3}$$

$$Z_{2}^{3}$$

$$Z_{2}^{3}$$

$$Z_{3}$$

$$Z_{4}^{3}$$

$$Z_{2}^{3}$$

$$Z_{3}$$

$$Z_{4}^{3}$$

$$Z_{4}^{4}$$

$$Z_{4$$

or the pharmaceutically acceptable salts thereof

wherein R³ is a noninterfering substituent;

each Z is CR² or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N;

each R² is independently a noninterfering substituent;

L is a linker;

n is 0 or 1; and

Ar' is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.